Harmonization of Immune Biomarker Assays for Clinical Studies

See allHide authors and affiliations

Science Translational Medicine  09 Nov 2011:
Vol. 3, Issue 108, pp. 108ps44
DOI: 10.1126/scitranslmed.3002785

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Assays that measure a patient’s immune response play an increasingly important role in the development of immunotherapies. The inherent complexity of these assays and independent protocol development between laboratories result in high data variability and poor reproducibility. Quality control through harmonization—based on integration of laboratory-specific protocols with standard operating procedures and assay performance benchmarks—is one way to overcome these limitations. Harmonization guidelines can be widely implemented to address assay performance variables. This process enables objective interpretation and comparison of data across clinical trial sites and also facilitates the identification of relevant immune biomarkers, guiding the development of new therapies.

View Full Text

Stay Connected to Science Translational Medicine

Editor's Blog